Inhibitors of the growth factors TGF-β1 and VEGF showed greater inhibitory effects on leiomyoma cell viability than conventional drugs, indicating their potential as therapeutic agents for uterine leiomyoma. Here, TGFB1 is linked to leiomyoma.